Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.

A simplified schedule of high-dose chemotherapy (HDC) consisting of melphalan (140 mg m-2) plus VP16 (2.5 g m-2) given over 12-18 h together with autologous non-cryopreserved autologous bone marrow transplant (ABMT) was used for treatment of relapsed (37 patients) and refractory (seven patients) pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Seymour, L. K., Dansey, R. D., Bezwoda, W. R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033336/
https://www.ncbi.nlm.nih.gov/pubmed/8080741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033336/
https://www.ncbi.nlm.nih.gov/pubmed/8080741

Ejemplares similares